Physician profile
Amrish D Patel
NPI 1871755025
$8,583.16
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,928 · 2020: $553 · 2021: $948 · 2022: $984 · 2023: $151 · 2024: $17.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $169.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $4,635.67 | 2019-2020 | |
| Si-Bone, INC. | $626.63 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $491.73 | 2019-2023 | Relistor |
| Collegium Pharmaceutical, INC. | $401.14 | 2019-2023 | Belbuca, Xtampza |
| Assertio Therapeutics, INC. | $361.24 | 2019-2020 | |
| Horizon Therapeutics Plc | $255.34 | 2019-2022 | |
| Nevro Corp. | $242.67 | 2021 | |
| Medtronic, INC. | $167.74 | 2022 | |
| Abbott Laboratories | $150.35 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $131.58 | 2019-2021 | |
| Protega Pharmaceutials INC | $102.74 | 2022-2023 | Roxybond |
| Arteriocyte Medical Systems, INC. | $98.70 | 2022 | |
| Amgen INC. | $98.19 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $95.42 | 2019-2023 | Ztlido |
| Electronic Waveform Lab, INC. | $75.16 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $73.21 | 2019-2020 | |
| Zyla Life Sciences, INC. | $69.72 | 2019 | |
| Almatica Pharma LLC | $62.57 | 2021 | |
| Forte Bio-Pharma LLC | $56.04 | 2021-2022 | |
| Eisai INC. | $50.69 | 2021 | |
| Redhill Biopharma INC. | $48.43 | 2021 | |
| Pfizer INC. | $41.60 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.65 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $39.34 | 2022 | |
| Boston Scientific Corporation | $35.03 | 2019-2020 | |
| Radius Health, INC. | $25.55 | 2021 | |
| Daiichi Sankyo INC. | $18.28 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.81 | 2024 | Xarelto |
| Lilly USA, LLC | $17.51 | 2022 | |
| Zimvie INC. | $17.31 | 2022 | |
| Fidia Pharma USA INC. | $13.23 | 2020 | |
| Bioventus LLC | $12.84 | 2022 | |
| Athena Bioscience, LLC | $9.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amrish Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.